JP6254090B2 - 軸索再生および神経機能を促進するための方法および組成物 - Google Patents

軸索再生および神経機能を促進するための方法および組成物 Download PDF

Info

Publication number
JP6254090B2
JP6254090B2 JP2014537360A JP2014537360A JP6254090B2 JP 6254090 B2 JP6254090 B2 JP 6254090B2 JP 2014537360 A JP2014537360 A JP 2014537360A JP 2014537360 A JP2014537360 A JP 2014537360A JP 6254090 B2 JP6254090 B2 JP 6254090B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
necrostatin
halogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530881A (ja
JP2014530881A5 (enExample
Inventor
デメトリオス・ヴァッヴァス
Original Assignee
マサチューセッツ・アイ・アンド・イア・インファーマリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6254090(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by マサチューセッツ・アイ・アンド・イア・インファーマリー filed Critical マサチューセッツ・アイ・アンド・イア・インファーマリー
Publication of JP2014530881A publication Critical patent/JP2014530881A/ja
Publication of JP2014530881A5 publication Critical patent/JP2014530881A5/ja
Application granted granted Critical
Publication of JP6254090B2 publication Critical patent/JP6254090B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014537360A 2011-10-21 2012-10-22 軸索再生および神経機能を促進するための方法および組成物 Active JP6254090B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550191P 2011-10-21 2011-10-21
US61/550,191 2011-10-21
PCT/US2012/061324 WO2013059791A2 (en) 2011-10-21 2012-10-22 Methods and compositions for promoting axon regeneration and nerve function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017228601A Division JP6560325B2 (ja) 2011-10-21 2017-11-29 軸索再生および神経機能を促進するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2014530881A JP2014530881A (ja) 2014-11-20
JP2014530881A5 JP2014530881A5 (enExample) 2015-12-10
JP6254090B2 true JP6254090B2 (ja) 2017-12-27

Family

ID=47116494

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014537360A Active JP6254090B2 (ja) 2011-10-21 2012-10-22 軸索再生および神経機能を促進するための方法および組成物
JP2017228601A Expired - Fee Related JP6560325B2 (ja) 2011-10-21 2017-11-29 軸索再生および神経機能を促進するための方法および組成物
JP2019132740A Expired - Fee Related JP6861764B2 (ja) 2011-10-21 2019-07-18 軸索再生および神経機能を促進するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017228601A Expired - Fee Related JP6560325B2 (ja) 2011-10-21 2017-11-29 軸索再生および神経機能を促進するための方法および組成物
JP2019132740A Expired - Fee Related JP6861764B2 (ja) 2011-10-21 2019-07-18 軸索再生および神経機能を促進するための方法および組成物

Country Status (6)

Country Link
US (3) US20140357570A1 (enExample)
EP (1) EP2773341A2 (enExample)
JP (3) JP6254090B2 (enExample)
CA (1) CA2888805C (enExample)
HK (1) HK1203044A1 (enExample)
WO (1) WO2013059791A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
CL2013003785A1 (es) * 2013-12-30 2014-07-11 Univ Pontificia Catolica Chile Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos
WO2016094846A1 (en) * 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
SG11202006304SA (en) * 2017-12-31 2020-07-29 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
EP3781571B1 (en) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
RU2749634C1 (ru) * 2020-11-30 2021-06-16 Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации Способ моделирования лечения больных с двигательными и висцеральными расстройствами на лабораторных животных.
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
KR20250119466A (ko) * 2024-01-31 2025-08-07 (주)노보메디슨 캐스파제 저해제의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
DE69739105D1 (de) 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
JP2002534139A (ja) 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
WO2001028493A2 (en) * 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
AU1920501A (en) 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20030103945A1 (en) * 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
WO2003061519A2 (en) 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20050130877A1 (en) * 2003-03-14 2005-06-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitors
AU2004315596B2 (en) * 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20070298129A1 (en) 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
CA2633500A1 (en) * 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
CN102408470A (zh) 2005-12-23 2012-04-11 洛桑大学 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
JP5366812B2 (ja) * 2006-10-10 2013-12-11 プレジデント アンド フェロウズ オブ ハーバード カレッジ 化合物、スクリーニング、および治療方法
US20090022570A1 (en) * 2007-07-16 2009-01-22 Joe David Craig System, method and apparatus for feeding biomass into a pressurized vessel
CA2696349A1 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
US7622106B1 (en) 2009-03-06 2009-11-24 Board Of Regents, The University Of Texas System Necrosis assay
JP5723294B2 (ja) 2009-12-09 2015-05-27 北海道公立大学法人 札幌医科大学 スーパーオキシド製造方法、スーパーオキシド消去能評価方法、スーパーオキシド製造装置およびスーパーオキシド消去能評価装置
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders

Also Published As

Publication number Publication date
JP2014530881A (ja) 2014-11-20
CA2888805C (en) 2020-07-14
JP2018065838A (ja) 2018-04-26
JP6861764B2 (ja) 2021-04-21
HK1203044A1 (en) 2015-10-16
US20140357570A1 (en) 2014-12-04
WO2013059791A3 (en) 2013-07-11
WO2013059791A2 (en) 2013-04-25
CA2888805A1 (en) 2013-04-25
US20190117724A1 (en) 2019-04-25
JP6560325B2 (ja) 2019-08-14
EP2773341A2 (en) 2014-09-10
US10022419B2 (en) 2018-07-17
US10799552B2 (en) 2020-10-13
JP2019196381A (ja) 2019-11-14
US20160151442A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
JP6560325B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
US10617735B2 (en) Methods and compositions for preserving retinal ganglion cells
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
US10149884B2 (en) Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
CN101743015A (zh) 物质治疗患有青光眼和其它退化性眼部疾病的人的视力丧失的用途
JP2022065024A (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
JP2009538827A (ja) カンナビノイドおよび使用方法
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
CN110742891B (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
JP7706376B2 (ja) 神経修復方法
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
CA3111433C (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
Le The Neuroprotective Effects of SA-10 PLGA Nanoparticles in a Mouse Model of Retinal Ischemia/Reperfusion Injury
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
HK40020385A (en) Composition for reducing nervous system injury and method of making and use thereof
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171129

R150 Certificate of patent or registration of utility model

Ref document number: 6254090

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RVTR Cancellation due to determination of trial for invalidation
R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250